A long term follow-up of a randomized trial comparing interferon-α with busulfan for chronic myelogenous leukemia

K. Ohnishi, M. Tomonaga, N. Kamada, K. Onozawa, A. Kuramoto, H. Dohy, H. Mizoguchi, S. Miyawaki, K. Tsubaki, Y. Miura, M. Omine, T. Kobayashi, T. Naoe, T. Ohshima, K. Hirashima, S. Ohtake, I. Takahashi, Y. Morishima, K. Naito, N. AsouM. Tanimoto, A. Sakuma, R. Ohno

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

To evaluate the long-term effectiveness of interferon-α (IFN-α) therapy in patients with chronic myelogenous leukemia (CML) in chronic phase, we examined the updated outcomes of 159 patients who had been enrolled between 1988 and 1991 into a randomized trial comparing IFN-α with busulfan. At a median follow-up of 73 months, the median survival was 71 months in the IFN-α group and 55 months in the busulfan group (P = 0.0563), and the median time of remaining in chronic phase was 58 months in the IFN-α group and 39 months in the busulfan group (P = 0.4676). Landmark analysis showed a significant advantage in survival (P = 0.009) and duration of chronic phase (P = 0.0001) in patients with any cytogenetic response among the IFN-α group. About half patients were discontinued IFN-α administration in spite of cytogenetic response in this study. It appears that continuation of IFN-α might possibly confer a survival advantage. Pretreatment factors associated with cytogenetic response included high hemoglobin level, low percentage of peripheral basophils and low leukocyte counts. Multivariate analysis identified lower percentage of bone marrow basophilia (P = 0.007) for survival advantage. If a group with a very good prognosis is predicted by a new prognostic model, it might be an option to wait for bone marrow transplantation.

Original languageEnglish
Pages (from-to)779-786
Number of pages8
JournalLeukemia Research
Volume22
Issue number9
DOIs
Publication statusPublished - Sep 1998
Externally publishedYes

Fingerprint

Busulfan
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interferons
Cytogenetics
Survival
Leukemia, Myeloid, Chronic Phase
Basophils
Bone Marrow Transplantation
Leukocyte Count
Hemoglobins
Multivariate Analysis
Bone Marrow

Keywords

  • Busulfan
  • Chronic myelogenous leukemia
  • Interferon-α
  • Prognostic factor
  • Randomized clinical trial

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

A long term follow-up of a randomized trial comparing interferon-α with busulfan for chronic myelogenous leukemia. / Ohnishi, K.; Tomonaga, M.; Kamada, N.; Onozawa, K.; Kuramoto, A.; Dohy, H.; Mizoguchi, H.; Miyawaki, S.; Tsubaki, K.; Miura, Y.; Omine, M.; Kobayashi, T.; Naoe, T.; Ohshima, T.; Hirashima, K.; Ohtake, S.; Takahashi, I.; Morishima, Y.; Naito, K.; Asou, N.; Tanimoto, M.; Sakuma, A.; Ohno, R.

In: Leukemia Research, Vol. 22, No. 9, 09.1998, p. 779-786.

Research output: Contribution to journalArticle

Ohnishi, K, Tomonaga, M, Kamada, N, Onozawa, K, Kuramoto, A, Dohy, H, Mizoguchi, H, Miyawaki, S, Tsubaki, K, Miura, Y, Omine, M, Kobayashi, T, Naoe, T, Ohshima, T, Hirashima, K, Ohtake, S, Takahashi, I, Morishima, Y, Naito, K, Asou, N, Tanimoto, M, Sakuma, A & Ohno, R 1998, 'A long term follow-up of a randomized trial comparing interferon-α with busulfan for chronic myelogenous leukemia', Leukemia Research, vol. 22, no. 9, pp. 779-786. https://doi.org/10.1016/S0145-2126(98)00082-4
Ohnishi, K. ; Tomonaga, M. ; Kamada, N. ; Onozawa, K. ; Kuramoto, A. ; Dohy, H. ; Mizoguchi, H. ; Miyawaki, S. ; Tsubaki, K. ; Miura, Y. ; Omine, M. ; Kobayashi, T. ; Naoe, T. ; Ohshima, T. ; Hirashima, K. ; Ohtake, S. ; Takahashi, I. ; Morishima, Y. ; Naito, K. ; Asou, N. ; Tanimoto, M. ; Sakuma, A. ; Ohno, R. / A long term follow-up of a randomized trial comparing interferon-α with busulfan for chronic myelogenous leukemia. In: Leukemia Research. 1998 ; Vol. 22, No. 9. pp. 779-786.
@article{9421323ba08b4786be6e8a2fb138a0e5,
title = "A long term follow-up of a randomized trial comparing interferon-α with busulfan for chronic myelogenous leukemia",
abstract = "To evaluate the long-term effectiveness of interferon-α (IFN-α) therapy in patients with chronic myelogenous leukemia (CML) in chronic phase, we examined the updated outcomes of 159 patients who had been enrolled between 1988 and 1991 into a randomized trial comparing IFN-α with busulfan. At a median follow-up of 73 months, the median survival was 71 months in the IFN-α group and 55 months in the busulfan group (P = 0.0563), and the median time of remaining in chronic phase was 58 months in the IFN-α group and 39 months in the busulfan group (P = 0.4676). Landmark analysis showed a significant advantage in survival (P = 0.009) and duration of chronic phase (P = 0.0001) in patients with any cytogenetic response among the IFN-α group. About half patients were discontinued IFN-α administration in spite of cytogenetic response in this study. It appears that continuation of IFN-α might possibly confer a survival advantage. Pretreatment factors associated with cytogenetic response included high hemoglobin level, low percentage of peripheral basophils and low leukocyte counts. Multivariate analysis identified lower percentage of bone marrow basophilia (P = 0.007) for survival advantage. If a group with a very good prognosis is predicted by a new prognostic model, it might be an option to wait for bone marrow transplantation.",
keywords = "Busulfan, Chronic myelogenous leukemia, Interferon-α, Prognostic factor, Randomized clinical trial",
author = "K. Ohnishi and M. Tomonaga and N. Kamada and K. Onozawa and A. Kuramoto and H. Dohy and H. Mizoguchi and S. Miyawaki and K. Tsubaki and Y. Miura and M. Omine and T. Kobayashi and T. Naoe and T. Ohshima and K. Hirashima and S. Ohtake and I. Takahashi and Y. Morishima and K. Naito and N. Asou and M. Tanimoto and A. Sakuma and R. Ohno",
year = "1998",
month = "9",
doi = "10.1016/S0145-2126(98)00082-4",
language = "English",
volume = "22",
pages = "779--786",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - A long term follow-up of a randomized trial comparing interferon-α with busulfan for chronic myelogenous leukemia

AU - Ohnishi, K.

AU - Tomonaga, M.

AU - Kamada, N.

AU - Onozawa, K.

AU - Kuramoto, A.

AU - Dohy, H.

AU - Mizoguchi, H.

AU - Miyawaki, S.

AU - Tsubaki, K.

AU - Miura, Y.

AU - Omine, M.

AU - Kobayashi, T.

AU - Naoe, T.

AU - Ohshima, T.

AU - Hirashima, K.

AU - Ohtake, S.

AU - Takahashi, I.

AU - Morishima, Y.

AU - Naito, K.

AU - Asou, N.

AU - Tanimoto, M.

AU - Sakuma, A.

AU - Ohno, R.

PY - 1998/9

Y1 - 1998/9

N2 - To evaluate the long-term effectiveness of interferon-α (IFN-α) therapy in patients with chronic myelogenous leukemia (CML) in chronic phase, we examined the updated outcomes of 159 patients who had been enrolled between 1988 and 1991 into a randomized trial comparing IFN-α with busulfan. At a median follow-up of 73 months, the median survival was 71 months in the IFN-α group and 55 months in the busulfan group (P = 0.0563), and the median time of remaining in chronic phase was 58 months in the IFN-α group and 39 months in the busulfan group (P = 0.4676). Landmark analysis showed a significant advantage in survival (P = 0.009) and duration of chronic phase (P = 0.0001) in patients with any cytogenetic response among the IFN-α group. About half patients were discontinued IFN-α administration in spite of cytogenetic response in this study. It appears that continuation of IFN-α might possibly confer a survival advantage. Pretreatment factors associated with cytogenetic response included high hemoglobin level, low percentage of peripheral basophils and low leukocyte counts. Multivariate analysis identified lower percentage of bone marrow basophilia (P = 0.007) for survival advantage. If a group with a very good prognosis is predicted by a new prognostic model, it might be an option to wait for bone marrow transplantation.

AB - To evaluate the long-term effectiveness of interferon-α (IFN-α) therapy in patients with chronic myelogenous leukemia (CML) in chronic phase, we examined the updated outcomes of 159 patients who had been enrolled between 1988 and 1991 into a randomized trial comparing IFN-α with busulfan. At a median follow-up of 73 months, the median survival was 71 months in the IFN-α group and 55 months in the busulfan group (P = 0.0563), and the median time of remaining in chronic phase was 58 months in the IFN-α group and 39 months in the busulfan group (P = 0.4676). Landmark analysis showed a significant advantage in survival (P = 0.009) and duration of chronic phase (P = 0.0001) in patients with any cytogenetic response among the IFN-α group. About half patients were discontinued IFN-α administration in spite of cytogenetic response in this study. It appears that continuation of IFN-α might possibly confer a survival advantage. Pretreatment factors associated with cytogenetic response included high hemoglobin level, low percentage of peripheral basophils and low leukocyte counts. Multivariate analysis identified lower percentage of bone marrow basophilia (P = 0.007) for survival advantage. If a group with a very good prognosis is predicted by a new prognostic model, it might be an option to wait for bone marrow transplantation.

KW - Busulfan

KW - Chronic myelogenous leukemia

KW - Interferon-α

KW - Prognostic factor

KW - Randomized clinical trial

UR - http://www.scopus.com/inward/record.url?scp=0032171177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032171177&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(98)00082-4

DO - 10.1016/S0145-2126(98)00082-4

M3 - Article

C2 - 9716008

AN - SCOPUS:0032171177

VL - 22

SP - 779

EP - 786

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 9

ER -